
# Skin and Soft Tissue Infection (ED)


**Evidence Based Outcome Center** 





Skin and Soft Tissue Infection (Inpatient) Evidence Based Outcome Center







Last Updated: March 9, 2021

# Skin and Soft Tissue Infection **Evidence Based Outcome Center**



#### History

- Fever, other systemic symptoms Number and location of abcess(es) •
- • Druation of lesion
- •
- Rapidity of spread Previous history of pustule, •
- abscess, folliculitis Family history or abscess, MRSA Break in skin barrier •
- Abrasion Insect bite

- •
- Dermatologic condition Concern for possible foreign body Infection due to animal bite Previous antibiotic use, including topical antibiotics •
- topical antibiotics
- Previous home remedies •


#### **Physical Exam**

- Assess Vital Signs, pain Location, size of lesion . •
- (measure, outline, photograph) Induration, swelling, fluctuance, erythema, ulceration, eschar, or lymphangitic streaking •
- .
- Spontaneous drainage Overlying or surrounding • cellulitis Regional adenopathy

.

Rash or existing skin condition •

# **Picture Atlas:**




Ultrasound abscess with surrounding Cellulitis



Cellulitis (Non-purulent)





<u>Ultrasound</u>

- Findings consistent with cellulitis
- Tissue edema
- "Cobblestoning"
- Helpful in differentiating cellulitis from abscess





## DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER



# Addendum 1: Guideline for SSTI Antibiotic Selection and Dosing

Disposition	Medication	Dosing Regimen
Non-Purulent Cellulitis: First-Line^		
Sepsis/SIRS	Refer to Sepsis ED/Inpatient guideline for antimicrobial recommendations	
Inpatient	Cefazolin (IV)	33 mg/kg/dose IV q8h (max 1000 mg/dose)
Outpatient	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)
Non-Purulent Cellulitis: History of Type I reaction or SEVERE adverse reaction to Cefazolin		
Inpatient	Vancomycin (IV)	See Vancomycin Dosing Guideline
Outpatient	Clindamycin (PO)	10 mg/kg/dose PO q8h (max 450 mg/dose PO)
Purulent Cellulitis: First-Line		
Sepsis/SIRS	Refer to Sepsis ED/Inpatient guideline for antimicrobial recommendations	
Inpatient without systemic signs of infection	Clindamycin (IV)	13 mg/kg/dose IV q8h (max 600 mg/dose)
	SMX/TMP* (PO)	5 mg/kg/dose of TMP* PO q12h (max 320 mg of TMP/dose)
Outpatient	SMX/TMP* (PO)	5 mg/kg/dose of TMP* PO q12h (max 320 mg of TMP/dose)
Outpatient (If MSSA)	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)
Purulent Cellulitis: History of Type I reaction or SEVERE adverse reaction to Sulfa		
Inpatient (If MRSA susceptible to clindamycin)	Clindamycin (IV)	13 mg/kg/dose IV q8h (max 600 mg/dose)
Inpatient	Vancomycin (IV)	See Vancomycin Dosing Guideline
Outpatient	Doxycycline (PO) ≥8 years only	2 mg/kg/dose PO q12h(max 100 mg/dose)
Outpatient (If MRSA susceptible to clindamycin)	Clindamycin (PO)	10 mg/kg/dose PO q8h (max 450 mg/dose PO)
Outpatient (If MSSA)	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)

\*SMX/TMP: sulfamethoxazole/trimethoprim

^ SMX/TMP recommended if personal or family history of MRSA; Avoid using SMX/TMP if abscess has not been drained





EBOC Project Owner: Jennifer Hughes, MD, FAAP

Approved by the Pediatric Evidence-Based Outcomes Center Team

## **Revision History**

Original Date Approved: March 2021 Next Review Date: March 2023

### SSTI EBOC Team:

Kathryn Merkel, PharmD Leah Jorgensen, DO Jason Gillon, MD Peter Gilbreath, MD Nalinda Charnsangavej, MD Claire Hebner, MD Ayesha Irani, DO Julia Sapozhnikov, PharmD Eric Grethel, MD Marisol Fernandez, MD Logan Rencher, DO Nalinda Charnsangavej, MD Julio Ortiz, MD Ronda Machen, PharmD Coburn Allen, MD Carmen Garudo, PM

## EBOC Committee:

Lynn Thoreson, DO Sarmistha Hauger, MD Terry Stanley, DNP Sujit Iyer, MD Tory Meyer, MD Nilda Garcia, MD Meena Iyer, MD Amanda Puro, MD